The research team, led by Noémie Brassard-Jollive, Yoann Atlas, and senior authors Laurent Muller and Catherine Monnot at the Center for Interdisciplinary Research in Biology at the Collège de France, together with collaborators across Paris institutions including the Hôpital Saint-Louis pathology network, began by examining actual human ccRCC specimens at high resolution. Clear cell renal cell carcinoma is the most common form of kidney cancer and is driven overwhelmingly by loss of the von Hippel-Lindau (VHL) tumor suppressor. VHL protein normally tags hypoxia-inducible factors for destruction; without it, hypoxia signaling runs constitutively, flooding the tumor with vascular endothelial growth factor (VEGF) and other pro-angiogenic programs. The consequence is the striking hypervascularization familiar to any pathologist. But VHL loss also promotes epithelial-to-mesenchymal transition (EMT), a phenotypic switch in which epithelial tumor cells acquire invasive, migratory, fibroblast-like traits, and this connection between invasiveness and vessel architecture turned out to be central to the new findings.

Within the patient samples, the investigators identified two vascular structures that are morphologically distinct from ordinary tumor capillaries. They named them ponds and sheets. High-resolution three-dimensional imaging of optically cleared patient-derived xenografts, essentially fragments of human tumor grown in mice and rendered transparent so that confocal microscopy could reconstruct the full vascular volume, revealed the striking geometry of these structures. Ponds appeared as large, irregular, reservoir-like formations with wide luminal cavities, vessels dilated far beyond anything resembling normal capillary caliber. Sheets, by contrast, were thin, elongated ribbons that appeared partially collapsed, as if the endothelial tubes had been flattened or incompletely organized. Neither resembles the narrow, regularly branching capillaries that pathologists count when they measure microvessel density, a metric whose prognostic value in ccRCC has proven disappointingly limited. The implication is that vessel quantity matters less than vessel architecture, and that the architecture has been largely invisible to conventional two-dimensional histology.

Capturing these structures in patients was only the first step. The team then engineered an in vitro model capable of reproducing them, because no existing laboratory system had recapitulated ccRCC vascular morphology faithfully enough to support drug testing. Their solution was a three-dimensional co-culture in which EMT-like tumor spheroids, compact spheres of tumor cells exhibiting the mesenchymal phenotype associated with VHL loss and invasion, are embedded in a dense collagen matrix alongside human endothelial cells. Collagen hydrogels of defined fibrillar density provide a physiologically relevant extracellular scaffold, and as the spheroids invade outward and the endothelial cells assemble into capillary-like networks, the two compartments interact. Crucially, the co-culture spontaneously generated structures mimicking pond architecture, whereas endothelial cells cultured alone formed conventional capillary networks. The tumor cells, in their invasive, EMT-like state, were actively instructing the formation of aberrant vascular geometry.

Time-lapse live imaging made it possible to watch this process unfold and revealed a temporal coupling that the authors describe as a link between tumor invasion and pond morphogenesis. The aberrant dilated structures did not arise independently of tumor behavior; they emerged in concert with the outward movement of invasive tumor cells, suggesting that the mechanical and biochemical traffic between invading spheroids and adjacent endothelium drives vessels into these pathological configurations. This observation ties together two features of ccRCC biology that are usually studied separately: the EMT-driven invasive program of the tumor cells and the angiogenic program of the vasculature. In this model they are two faces of a single coordinated behavior, orchestrated in part by the VHL-deficient tumor microenvironment.

The pharmacological payoff came when the team exposed the system to clinically relevant targeted therapies: temsirolimus, an mTOR inhibitor; crizotinib, a tyrosine kinase inhibitor; and sunitinib, the multi-target VEGF receptor blocker that has long anchored first-line treatment of metastatic ccRCC. In monoculture, meaning endothelial cells alone forming capillaries, and in tumor spheroid monoculture, the drugs impaired capillary morphogenesis and tumor invasion to varying degrees, consistent with known clinical activity. But when the co-culture was treated, overall drug efficacy dropped. The presence of both cell types together created a microenvironment in which the same compounds that worked well on isolated compartments became substantially less effective, an in vitro echo of the resistance that frustrates oncologists in the clinic.

The most provocative finding concerned sunitinib specifically. When the researchers analyzed the drug’s effects structure by structure within the co-culture, the pond-like formations showed markedly reduced sensitivity compared with the adjacent, more conventional capillaries. In other words, a single drug at a single concentration could silence one vascular compartment while leaving another largely intact, within the same three-dimensional culture. If ponds behave this way in patients, they would provide persistent vascular supply through the course of therapy, functioning as a structural reservoir of resistance even when standard capillaries regress. This offers a mechanistic candidate for the well-documented phenomenon of anti-angiogenic resistance in ccRCC, which has previously been attributed mostly to compensatory signaling pathways, hypoxic adaptation, and alternative pro-angiogenic factors rather than to the physical heterogeneity of the vessels themselves.

The study also carries a methodological message for the field. Two-dimensional assays, endothelial tube formation on flat Matrigel and microvessel density counts on tissue sections, dominate angiogenesis research, and the authors argue that these approaches fundamentally cannot detect structures like ponds and sheets, whose defining features are volumetric. The consensus is already shifting; recent volumetric imaging studies of ccRCC microvasculature have shown that three-dimensional vascular patterns correlate with tumor genomics and patient outcomes where density measurements fail. By combining optically cleared xenografts with a tractable in vitro co-culture that reproduces key pathological structures, the Paris team has supplied a platform on which candidate therapies can be evaluated not just for whether they reduce vessel number but for whether they eliminate the specific vascular geometries associated with invasion and drug failure.

Clinically, the identification of ponds as candidate contributors to treatment failure suggests several concrete directions. If pond formation is driven by EMT-like tumor cells, then targeting the invasive phenotype itself, or the tumor-endothelial signals that mediate pond morphogenesis, might sensitize these structures to VEGF blockade. Combination regimens pairing VEGF inhibitors with agents active against EMT-associated or mTOR-dependent pathways could be re-evaluated in the co-culture model before committing patients. And because the platform is built from human cells in a defined matrix, it could eventually support personalized testing, growing a patient’s own tumor cells in spheroid-endothelial co-culture to predict which targeted regimen will best dismantle the individual tumor’s vascular architecture.

For now, the immediate contribution is conceptual: ccRCC vasculature is not a uniform target but a heterogeneous collection of structures, some of which are intrinsically harder to drug than others, and the road to durable responses may run through the ones that pathologists’ slides have been flattening into invisibility. The study, published as volume 29, article 56 of Angiogenesis in August 2026, reorients attention from how many vessels a tumor has to what kind of vessels it has, and in doing so turns a laboratory curiosity, a dilated cavity in a collagen gel, into a plausible answer to one of kidney cancer’s most stubborn clinical questions.

Renal cell carcinoma, representing the most common type of kidney cancer, manifests in various pathological forms, with clear cell renal cell carcinoma (ccRCC) being the most prevalent. In contrast, non-clear cell RCC (non-ccRCC) encompasses several less common variants, each with distinct biological behaviors and prognoses. While prior studies have extensively examined genetic and molecular determinants, the role of the tumor microenvironment, particularly the surrounding adipose tissue, has remained relatively underexplored until now.

The study employed a rigorous retrospective analysis of 297 RCC patients, stratifying them into two groups based on pathological diagnosis: 236 patients with ccRCC and 61 with non-ccRCC. Utilizing computed tomography (CT) imaging technology, the researchers quantified the perirenal fat area by measuring cross-sectional fat deposits at the renal vein level. This precise imaging-based assessment allowed for accurate correlations between fat volume and tumor characteristics to emerge from the data.

One of the critical findings was the identification of significant differences in perirenal fat areas between ccRCC and non-ccRCC groups. Patients diagnosed with ccRCC exhibited notably higher PFA measurements, contrasted with their non-ccRCC counterparts. Additionally, differences extended beyond fat area measurements to include clinical variables such as body weight and body mass index (BMI), both indicators of overall adiposity and metabolic health, which were found to differ significantly between the groups.

Importantly, the analysis did not merely stop at univariate observations. By deploying a multivariate logistic regression model, the investigators provided a nuanced understanding of how PFA independently correlates with RCC subtype likelihood, after adjusting for potential confounders. This approach reinforced the validity of their findings and suggested a more direct biological linkage between adipose tissue quantity and tumor phenotype, particularly in the context of clear cell carcinoma.

The spatial dimension of tumor location within the kidney emerged as another pivotal factor. Notably, when tumors were located outside the polar lines of the kidney (OPLK)—essentially the non-polar, midsection region of the organ—the association between PFA and ccRCC risk was accentuated. Quantitatively, each incremental increase of 1 cm² in perirenal fat area corresponded to a 5% heightened probability of the tumor being the clear cell subtype. This spatial dependency emphasizes that tumor microenvironmental factors, including regional fat deposition, may play different roles depending on anatomical tumor localization.

Further stratification still refined these insights. Focusing on patients within pathological stage T1 (denoting early-stage tumors confined to the kidney), the link between PFA and ccRCC became even more pronounced for tumors situated outside the polar lines. In such cases, every 1 cm² increase in PFA was associated with a 6% rise in ccRCC likelihood. Early-stage tumors represent a critical therapeutic window, so understanding factors that may predict pathological subtype at this stage holds clinical significance for personalized patient management.

These findings collectively hint at perirenal adipose tissue not just as a passive anatomical structure but potentially as an active player influencing RCC development and phenotypic expression. The metabolic and paracrine functions of adipose tissue could foster a microenvironment conducive to the pathogenesis or progression of clear cell carcinomas. Adipocytes are known to secrete a variety of bioactive molecules, including adipokines, cytokines, and growth factors, which can orchestrate inflammatory and signaling cascades relevant to tumor biology.

Intriguingly, the study also detected significant correlations with pathological staging, where certain stages demonstrated disparities in PFA between ccRCC and non-ccRCC groups. This suggests that perirenal fat’s influence might extend beyond mere tumor initiation to potentially affect tumor progression kinetics or aggressiveness. It underscores the need to consider fat tissue characteristics when evaluating tumor staging and designing intervention strategies.

The clinical implications are manifold. Firstly, leveraging PFA measurements through readily available CT imaging might serve as an adjunct predictive biomarker for RCC pathological type before invasive biopsy or surgery. Such non-invasive stratification could optimize surgical planning and patient counseling. Secondly, recognizing perirenal fat as a risk factor invites exploration into metabolic modulation or therapeutics targeting adipose tissue biology to indirectly influence tumor behavior.

In the broader context of cancer research, this study reinforces a growing paradigm where the tumor microenvironment, inclusive of adipose tissue, actively contributes to oncogenesis and tumor heterogeneity. It demands a multidisciplinary approach combining radiologic imaging, pathology, and molecular biology to unravel intricate tumor-host interactions. The novel observation of spatial dependency in the fat-tumor relationship opens avenues for further research to clarify mechanistic underpinnings.

Moreover, such data stimulate questions concerning lifestyle and systemic factors influencing perirenal fat accumulation, including obesity and metabolic syndrome, potentially linking systemic metabolic health with oncologic risks at organ-specific levels. This raises prospects for preventive strategies focusing on weight management and metabolic control as adjuncts to reduce RCC risk or improve prognosis.

Given the retrospective nature of the study, prospective cohort research and experimental models will prove essential to affirm causality and elucidate the molecular mechanisms by which perirenal adiposity modulates tumorigenesis. Biomolecular profiling of adipose tissue adjacent to tumors, alongside detailed phenotyping of ccRCC versus non-ccRCC cells, may unearth novel therapeutic targets embedded within the tumor microenvironment.

In summary, this comprehensive examination highlights a tangible association between perirenal fat area and clear cell renal carcinoma, particularly emphasizing the significance of tumor anatomical positioning within the kidney. These findings have the potential to reshape clinical perspectives on RCC risk assessment and pave the way for integrative approaches leveraging metabolic and anatomical biomarkers. As renal cancer remains a formidable clinical challenge globally, such insights carry promise for enhanced patient outcomes through more personalized care paradigms.

Subject of Research: The relationship between pathological types of renal cell carcinoma and perirenal fat area.

Article Title: The relationship between renal cell carcinoma pathological types and perirenal fat area.

Article References:
Leng, X., Zhou, C., Wu, J. et al. The relationship between renal cell carcinoma pathological types and perirenal fat area. BMC Cancer 25, 841 (2025). https://doi.org/10.1186/s12885-025-14164-2

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14164-2